Advanced search
Publication Cover
Journal of Obstetrics and Gynaecology Volume 42, 2022 - Issue 7
Submit an article Journal homepage
72
Views
1
CrossRef citations to date
0
Altmetric
Research Aricles

Ultrasonographic appearance of the endometrium after saline infusion in women presenting with PRM-associated endometrial changes, due to the use of ulipristal acetate

Stefan Cosynsa Department of Gynecology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZBrussel), Brussels, BelgiumCorrespondence[email protected]
,
Noëlie Donya Department of Gynecology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZBrussel), Brussels, Belgium
,
Herman Tournayeb Department of Fertility, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZBrussel), Brussels, Belgium
&
Nikolaos P. Polyzosc Department of Fertility, Dexeus University Hospital, Barcelona, Spain
Pages 2888-2892 | Published online: 26 Aug 2022

References

  • Anon. 2014. Committee Opinion No. 601: tamoxifen and uterine cancer. Obstetrics & Gynecology 123:1394–1397.
  • Achiron R, Lipitz S, Sivan E, Goldenberg M, Horovitz A, Frenkel Y, Mashiach S. 1995. Changes mimicking endometrial neoplasia in postmenopausal, tamoxifen-treated women with breast cancer: a transvaginal Doppler study. Ultrasound in Obstetrics and Gynecology 6:116–120.
  • Bettocchi S, Baranowski WE, Doniec J, Ceci O, Resta L, Fascilla FD, et al. 2016. Hysteroscopic patterns in women on treatment with ulipristal acetate 5 mg/day: a preliminary study. Journal of Minimally Invasive Gynecology 23:664–669.
  • Courtoy GE, Donnez J, Marbaix E, Dolmans M-M. 2015. In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment. Fertility and Sterility 104:426–434.e1.
  • De Milliano I, Van Hattum D, Ket JCF, Huirne JAF, Hehenkamp WJK. 2017. Endometrial changes during ulipristal acetate use: a systematic review. European Journal of Obstetrics, Gynecology, and Reproductive Biology 214:56–64.
  • Donnez J, Donnez O, Matule D, Ahrendt HJ, Hudecek R, Zatik J, et al. 2016. Long-term medical management of uterine fibroids with ulipristal acetate. Fertility and Sterility 105:165–173.e4.
  • Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. 2012. Ulipristal acetate versus placebo for fibroid treatment before surgery. New England Journal of Medicine 366:409–420.
  • Donnez J, Tomaszewski J, Vázquez F, Bouchard P, Lemieszczuk B, Baró F, et al. 2012. Ulipristal acetate versus leuprolide acetate for uterine fibroids. New England Journal of Medicine 366:421–432.
  • Donnez J, Vázquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, et al. 2014. Long-term treatment of uterine fibroids with ulipristal acetate. Fertility and Sterility 101:1565–1573.e1-18.
  • Fiscella J, Bonfiglio T, Winters P, Eisinger SH, Fiscella K. 2011. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Human Pathology 42:947–953.
  • Gracia M, Nonell R, Ros C, Rius M, Quintas L, Martínez-Zamora M, Carmona F. 2019. Sonographic and hysteroscopic endometrial examination in women treated with ulipristal acetate: exploratory findings at a tertiary referral center. European Journal of Obstetrics & Gynecology and Reproductive Biology 232:40–45.
  • Horne FM, Blithe DL. 2007. Progesterone receptor modulators and the endometrium: changes and consequences. Human Reproduction Update 13:567–580.
  • Ioffe OB, Zaino RJ, Mutter GL. 2009. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Modern Pathology 22:450–459.
  • Markovitch O, Tepper R, Aviram R, Fishman A, Shapira J, Cohen I. 2004. The value of sonohysterography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients. Gynecologic Oncology 94:754–759.
  • Munro MG, Critchley HO, Broder MS, Fraser IS, FIGO Working Group on Menstrual Disorders. 2011. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. International Journal of Gynaecology and Obstetrics 113:3–13.
  • Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, et al. 2008. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology 21:591–598.
  • Strauss HG, Wolters M, Methfessel G, Buchmann J, Koelbl H. 2000. Significance of endovaginal ultrasonography in assessing tamoxifen-associated changes of the endometrium. A prospective study. Acta Obstetricia et Gynecologica Scandinavica 79:697–701.
  • Williams AR, Bergeron C, Barlow DH, Ferenczy A. 2012. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. International Journal of Gynecological Pathology 31:556–569.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.